MIKLIK, Roman, Marie MIKLÍKOVÁ, Radim SPACEK, Jindřich ŠPINAR, Kamil ZEMAN, Klára BENEŠOVÁ, Marián FELŠÖCI, Lidka POHLUDKOVA, Ladislav DUŠEK, Jiří JARKOVSKÝ, Petr LOKAJ, Ilona PARENICOVA a Jiří PAŘENICA. Differences in risk profiles and long-term outcomes in acute heart failure patients with preserved and reduced left ventricular ejection fraction in the Czech Republic: The AHEAD registry sub-analysis. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2021, roč. 165, č. 1, s. 34-42. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2020.038.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Differences in risk profiles and long-term outcomes in acute heart failure patients with preserved and reduced left ventricular ejection fraction in the Czech Republic: The AHEAD registry sub-analysis
Autoři MIKLIK, Roman (203 Česká republika), Marie MIKLÍKOVÁ (203 Česká republika, domácí), Radim SPACEK (203 Česká republika), Jindřich ŠPINAR (203 Česká republika, domácí), Kamil ZEMAN (203 Česká republika), Klára BENEŠOVÁ (203 Česká republika, domácí), Marián FELŠÖCI (703 Slovensko), Lidka POHLUDKOVA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Petr LOKAJ (203 Česká republika, domácí), Ilona PARENICOVA (203 Česká republika) a Jiří PAŘENICA (203 Česká republika, domácí).
Vydání Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2021, 1213-8118.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 20601 Medical engineering
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 1.648
Kód RIV RIV/00216224:14110/21:00122112
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.5507/bp.2020.038
UT WoS 000629606300006
Klíčová slova anglicky acute heart failure; left ventricular ejection fraction; rehospitalization; AHEAD; mortality
Štítky 14110211, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 18. 8. 2021 10:06.
Anotace
Background. The latest European heart failure guidelines define patients as those with reduced (HFrEF), mid-range, and preserved (HFpEF) left ventricular ejection fraction (LVEF; <40%, 40%-49%, and >= 50%, respectively). We investigated the causes of rehospitalizations/deaths in our institution's heart failure patients and focused on differences in the clinical presentation, risk profile, and long-term outcomes between the HFrEF and HFpEF groups in a real-life scenario. Methods and Results. We followed 1274 patients discharged from heart failure hospitalization in 2 centres. The mean patient age was 75.9 years, and men and women were represented equally. During the minimal follow-up of 2 years, 57% of patients were hospitalised for any cause, 24.9% for decompensated heart failure, and 43.3% for any cardiovascular cause. A total of 36.1% of patients died, either with prior (11.8%) or without prior (24.3%) heart failure rehospitalization. Heart failure was also the most frequent cause of cardiovascular hospitalization, followed by gastrointestinal problems, infections, and tumours for noncardiovascular hospitalizations. Patients with HFrEF had different baseline characteristics and risk profiles, experienced more hospitalizations for acute heart failure (28.6% vs 20.2%, P=0.012), and had higher cardiovascular mortality (82.4% vs 63.5%, P<0.001) when compared with HFpEF patients. Overall mortality and rehospitalization rates were similar. Conclusion. Within 2 years, half of the patients died and/or were hospitalised for acute decompensation of heart failure, and only one-third of the patients survived without any hospitalization. HFrEF and HFpEF patients were confirmed to be different entities with diverse characteristics, risk profiles, and cardiovascular event rates.
Návaznosti
MUNI/A/1250/2017, interní kód MUNázev: Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii
Investor: Masarykova univerzita, Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty
VytisknoutZobrazeno: 24. 6. 2024 23:03